文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

2型糖尿病作为COVID-19严重结局的预测因素——一项系统评价和荟萃分析

Type 2 diabetes mellitus as a predictor of severe outcomes in COVID-19 - a systematic review and meta-analyses.

作者信息

Fatoke Babatunde, Hui Amrit Lal, Saqib Muhammad, Vashisth Mrinal, Aremu Stephen Olaide, Aremu Dorcas Oluwakemi, Aremu Deborah Bukola

机构信息

General Hospital Lagos, Odan, Lagos Island, Lagos State, Nigeria.

Faculty of General Medicine, Siberian State Medical University, Tomsk, 634050, Russia.

出版信息

BMC Infect Dis. 2025 May 19;25(1):719. doi: 10.1186/s12879-025-11089-w.


DOI:10.1186/s12879-025-11089-w
PMID:40389865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12090609/
Abstract

BACKGROUND: The COVID-19 pandemic has posed significant challenges to global health, with type 2 diabetes mellitus (T2DM) emerging as a key risk factor for adverse outcomes. This study systematically reviews and quantifies the association between T2DM and COVID-19 outcomes, including mortality, severity, and need for mechanical ventilation. METHODS: A systematic review and meta-analysis were conducted that adhered to PRISMA guidelines. We searched PubMed, Scopus, Web of Science and Embase for studies published from december 2019 to march 2024. Eligible studies reported on the impact of T2DM on COVID-19 outcomes in the adult population. Data were extracted and analyzed using a random-effects model, and heterogeneity was assessed using the I statistic. Publication bias was assessed using Egger regression, Kendall's Tau, and the Fail-safe N calculation. RESULTS: Eighteen studies were included in the meta-analysis for mortality, six for severity and five for mechanical ventilation. T2DM was significantly associated with higher mortality (OR = 3.66, 95% CI: 2.20-5.11, p < 0.001), higher severity (OR = 1.97, 95% CI: 1.02-2.92, p < 0.001), and higher need for mechanical ventilation (OR = 2.34, 95% CI: 1.18-3.49, p < 0.001). Heterogeneity was high for mortality (I = 83.83%) but low for severity and mechanical ventilation (I = 0%). No significant publication bias was found. CONCLUSIONS: T2DM is associated with significantly worse outcomes in COVID-19 patients, including higher mortality, higher severity and a greater likelihood of needing mechanical ventilation. These findings emphasize the need for targeted interventions and management strategies for individuals with T2DM during the ongoing pandemic. Future research should focus on understanding the underlying mechanisms and exploring strategies to mitigate these risks.

摘要

背景:新冠疫情给全球健康带来了重大挑战,2型糖尿病(T2DM)已成为不良后果的关键风险因素。本研究系统回顾并量化了T2DM与新冠疫情结局之间的关联,包括死亡率、严重程度以及机械通气需求。 方法:按照PRISMA指南进行了系统回顾和荟萃分析。我们在PubMed、Scopus、科学网和Embase中检索了2019年12月至2024年3月发表的研究。符合条件的研究报告了T2DM对成年人群新冠疫情结局的影响。使用随机效应模型提取和分析数据,并使用I统计量评估异质性。使用Egger回归、肯德尔tau系数和失安全数计算评估发表偏倚。 结果:纳入荟萃分析的研究中,18项涉及死亡率,6项涉及严重程度,5项涉及机械通气。T2DM与较高的死亡率(比值比[OR]=3.66,95%置信区间[CI]:2.20-5.11,p<0.001)、较高的严重程度(OR=1.97,95%CI:1.02-2.92,p<0.001)以及较高的机械通气需求(OR=2.34,95%CI:1.18-3.49,p<0.001)显著相关。死亡率的异质性较高(I=83.83%),但严重程度和机械通气的异质性较低(I=0%)。未发现显著的发表偏倚。 结论:T2DM与新冠患者明显更差的结局相关,包括更高的死亡率、更高的严重程度以及更高的机械通气需求可能性。这些发现强调了在当前疫情期间对T2DM患者采取针对性干预措施和管理策略的必要性。未来的研究应专注于了解潜在机制并探索降低这些风险的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4291/12090609/a4ff456021c9/12879_2025_11089_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4291/12090609/9eeb93d9251e/12879_2025_11089_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4291/12090609/4ba496e3c30c/12879_2025_11089_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4291/12090609/203caac933b5/12879_2025_11089_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4291/12090609/a4ff456021c9/12879_2025_11089_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4291/12090609/9eeb93d9251e/12879_2025_11089_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4291/12090609/4ba496e3c30c/12879_2025_11089_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4291/12090609/203caac933b5/12879_2025_11089_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4291/12090609/a4ff456021c9/12879_2025_11089_Fig4_HTML.jpg

相似文献

[1]
Type 2 diabetes mellitus as a predictor of severe outcomes in COVID-19 - a systematic review and meta-analyses.

BMC Infect Dis. 2025-5-19

[2]
Remdesivir for the treatment of COVID-19.

Cochrane Database Syst Rev. 2021-8-5

[3]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[4]
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.

Cochrane Database Syst Rev. 2021-5-20

[5]
Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).

PLoS One. 2021

[6]
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.

Cochrane Database Syst Rev. 2021-2-12

[7]
Obesity in patients with COVID-19: a systematic review and meta-analysis.

Metabolism. 2020-9-28

[8]
Variation in outcome of invasive mechanical ventilation between different countries for patients with severe COVID-19: A systematic review and meta-analysis.

PLoS One. 2021

[9]
Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis.

BMJ Evid Based Med. 2021-6

[10]
Ivermectin for preventing and treating COVID-19.

Cochrane Database Syst Rev. 2022-6-21

本文引用的文献

[1]
Diabetes and susceptibility to COVID-19: Risk factors and preventive and therapeutic strategies.

World J Diabetes. 2024-8-15

[2]
Utilization Patterns and Outcomes of People With Diabetes and COVID-19: Evidence From United States Medicare Beneficiaries in 2020.

Front Clin Diabetes Healthc. 2022-7-5

[3]
Susceptibility of Diabetic Patients to COVID-19 Infections: Clinico-Hematological and Complications Analysis.

Vaccines (Basel). 2023-3-1

[4]
Characteristics, Mortality, and Clinical Outcomes of Hospitalized Patients with COVID-19 and Diabetes: A Reference Single-Center Cohort Study from Poland.

Int J Endocrinol. 2023-2-16

[5]
COVID-19: Diabetes Perspective-Pathophysiology and Management.

Pathogens. 2023-1-25

[6]
COVID-19, Mental Health, and Chronic Illnesses: A Syndemic Perspective.

Int J Environ Res Public Health. 2023-2-13

[7]
The challenges brought by the COVID-19 pandemic to health systems exposed pre-existing gaps.

Health Policy Open. 2023-12

[8]
Global Challenges to Public Health Care Systems during the COVID-19 Pandemic: A Review of Pandemic Measures and Problems.

J Pers Med. 2022-8-7

[9]
Increased Risk of COVID-19 in Patients with Diabetes Mellitus-Current Challenges in Pathophysiology, Treatment and Prevention.

Int J Environ Res Public Health. 2022-5-27

[10]
COVID-19 infection: an overview on cytokine storm and related interventions.

Virol J. 2022-5-26

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索